IBD Collaborative: Therapeutic Drug Monitoring in IBD 3.29.22
The IBD Collaborative is a semi-annual, accredited gastroenterologist education series developed by the UPMC and AHN Inflammatory Bowel Disease Centers to educate the greater Pittsburgh gastroenterology community as well as domestic GI partners. This March 29th course has been designed for physicians and all medical professionals interested in IBD patient care.
- Implement IBD medications appropriately.
- Gain experience and confidence in IBD medication prescribing practices, especially related to proactive and reactive therapeutic drug monitoring.
- Refer IBD patients to advanced subspecialty care when warranted.
7:00 Welcome Sandra El-Hachem, MD and Marc Schwartz, MD
7:05 New Medications for IBD Marc Schwartz, MD
7:15 Debate: Therapeutic Drug Monitoring in IBD
Moderator: Sandra El-Hachem, MD
7:15 Proactive Monitoring Amir-Ali Ghaffari, MD, PhD
7:25 Reactive Monitoring Christina DiMaria, DO, RD
7:40 Discussion with Audience
The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, the UPMC Center for Continuing Education in the Health Sciences, UPMC / University of Pittsburgh Medical Center or Affiliates and University of Pittsburgh School of Medicine. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses
Sandra El-Hachem, MD
Marc Schwartz, MD
Amir-Ali Ghaffari, MD, PhD
Christina DiMaria, DO, RD
The following relevant financial relationships was disclosed: Sandra El-Hachem, MD is on the speakers' bureau for the following: Abbvie, Janssen, Pfizer, Takeda, UCB/Ferring, Prometheus, Bristol Myers Squibb
No other planners, members of the planning committee, speakers, presenters, authors, content reviewers and/or anyone else in a position to control the content of this education activity have relevant financial relationships to disclose.
Accreditation and credit designation
In support of improving patient care, the University of Pittsburgh is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The University of Pittsburgh School designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Other Healthcare Professionals
Other health care professionals will receive a certificate of attendance confirming the number of contact hours commensurate with the extent of participation in this activity.
- 1.00 AMA PRA Category 1 Credit™The University of Pittsburgh School of Medicine is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
- 1.00 Attendance
Bristol Myers Squibb
Takeda Pharmaceuticals America, Inc